The key takeaways for this program are:
- Understanding the Prometheus decision and what the Supreme Court did and did not say;
- Understanding the question at issue in Myriad and how it is similar—and different—from that decided in Prometheus;
- Learning possible patent claim strategies to protect personalized medicine methods and biotechnology inventions under the new paradigm;
- Reviewing the U.S. Patent Office Guidance to Examiners, issued shortly after the Supreme Court decided Prometheus; and
- Discussing Options for strengthening already granted patents.
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.